Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

文章核心观点 - 艾利利利公司(Eli Lilly)在9月3日上午10:31出现了一次"Power Inflow"事件,这表明交易环境从主要卖出转变为买入,显示投资者信心增强和对公司前景看好 [1][2] - "Power Inflow"是一种基于订单流分析的交易信号,通常出现在交易日开盘前两小时内,反映了机构投资者的活跃交易 [3] - 订单流分析有助于投资者更精确地评估市场动态,发现交易机会,提高交易成果,但同时也需要采取有效的风险管理策略 [4][5] 公司相关内容 - 艾利利利公司在9月3日上午10:31出现了一次"Power Inflow",股价从958.10美元上涨至11:37的965.94美元,涨幅为0.82% [1][2][5] - 尽管之后股价收于956.35美元,较"Power Inflow"时下跌0.02%,但这突出了制定包括获利目标和止损点在内的交易计划的重要性 [5] 行业相关内容 - 订单流分析或交易/市场流分析涉及对零售和机构交易者的买卖订单量的全面分析,以生成可操作的见解并改善交易决策 [3] - 这种方法特别擅长于识别积极交易者中的看涨信号 [3]

There's at least one key common denominator here: tremendous growth prospects.Don't want to think too hard about your investing decisions? Then go with the stocks of highly profitable companies with strong growth prospects.Three Motley Fool contributors identified several stocks that fit this description. Here's why they think Eli Lilly (LLY 2.11%), Novo Nordisk (NVO 1.19%), and Vertex Pharmaceuticals (VRTX 0.52%) are no-brainer healthcare stocks to buy in September.The growth machine that never runs out of ...

文章核心观点 - 艾利利利公司的新药物Mounjaro和Zepbound销售火爆,公司无需大量营销投入即可实现高速增长 [2] - 艾利利利公司的新药物Mounjaro和Zepbound的销售额已超过公司传统主打产品Trulicity,成为公司新的增长引擎 [3] - 艾利利利公司未来有望凭借Mounjaro和Zepbound实现更高的收入增长,股价仍有上涨空间 [4][5] 公司概况 - 艾利利利公司是一家大型制药公司,主要业务包括糖尿病和肥胖症治疗药物 [1][3] - 公司近年来业绩增长迅速,过去5年股价上涨770% [1] - 公司目前市值高达8500亿美元,市盈率达117倍,但仍有进一步上涨空间 [1][5] 新药销售情况 - 公司新推出的糖尿病药物Mounjaro和减肥药Zepbound销售火爆,需求强劲 [2][3] - Mounjaro和Zepbound的销售额已超过公司传统主打产品Trulicity,成为公司新的增长引擎 [3] - 公司新药物Verzenio的销售额也超过了Trulicity [3] 未来发展前景 - 公司新药Mounjaro和Zepbound有望在未来实现更高的销售额,为公司带来巨大收入增长 [4] - 分析师预测Mounjaro和Zepbound的潜在峰值销售额可达500亿美元 [4] - 公司未来有望凭借新药物实现持续高速增长,股价仍有较大上涨空间 [5]

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Eli Lilly (LLY) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Lilly currently has an average br ...

Some insurers don't cover Lilly's obesity drug. The company just gave patients a way around that problem.If the price is right, sales can soar. That's true with any product -- even prescription drugs.On Tuesday, Eli Lilly (LLY -0.58%) announced a new pricing plan for its latest blockbuster drug, Zepbound. The therapy will now be available to self-pay patients at a 50% or greater discount to the list price of other GLP-1 obesity drugs. Is Lilly stock a no-brainer buy after the company's Zepbound move? Why Li ...

Eli Lilly and Company (LLY) announced the launch of single-dose vials of its popular obesity drug, Zepbound (tirzepatide), to meet supply shortages in response to high demand. These 2.5 mg and 5 mg single-dose vials are priced at least 50% lower than the list price of competing GLP-1 medicines for obesity. A four-week supply of the 2.5 mg vials has been priced at $399 while the same for the 5 mg dose will cost $549. Zepbound is presently available in a single-dose pen (autoinjector). The vials should be eas ...

报告公司投资评级 - 目标价 959.49 美元，持有评级 [4] 报告的核心观点 公司业绩表现 - 2024Q2 公司营收 113 亿美元（同比+36%），毛利 91.3 亿美元（+40%），毛利率 80.8%（+2.2pp），净利润 29.67 亿美元（+56%）[1] - 收入端与利润端的强劲表现大超预期 [1] 主要产品表现 - 替尔泊肽强劲放量，2024Q2 代谢板块收入增长 50%至 75.1 亿美元 [2] - Mounjaro 销售环比增长 71%至 30.9 亿美元，Zepbound 销售环比增长 140%至 12.4 亿美元 [2] - 市场对 GLP-1 的需求强烈，产能是制约其放量的最主要因素 [2] 管线进展 - 阿贝西利保持高速增长（+44%），第三代 BTK 抑制剂 Pirtobrutinib 也取得了非常可观的放量（+540%） [3] - 新一代雌激素受体降解剂 Imlunestrant 将读出乳腺癌三期临床数据，并递交上市申请 [3] - Donanemab 在美国成功获批上市，有望在欧洲和日本获批 [3] 公司财务数据总结 - 营业收入 2024 年预测为 113 亿美元，同比增长 36% [1] - 毛利率 2024 年预测为 80.8%，同比提升 2.2个百分点 [1] - 净利率 2024 年预测为 26.3%，同比提升 3.4个百分点 [1] - 研发费用率 2024 年预测为 24%，同比下降 4.4个百分点 [1] - 销售及管理费用率 2024 年预测为 18.7%，同比下降 4.5个百分点 [1]

Key TakeawaysHims & Hers Health shares declined Tuesday after Eli Lilly said it would be offering a lower-priced version of its popular Zepbound weight-loss treatment.Lilly explained that the new product would be sent directly to consumers.Hims & Hers recently began offering a copycat version of Novo Nordisk's Wegovy and Ozempic, and planned to have one for Zepbound in the near future. Shares of Hims & Hers Health (HIMS) sank in intraday trading Tuesday on new competition for lower-priced weight-loss drugs ...

ROCKVILLE, Md., Aug. 27, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2024 class in AKF’s Corporate Membership Program as a Champion-level member. Boehringer Ingelheim and Lilly will help provide financial support for AKF’s work to advance kidney disease awareness, prevention, early detection, treatment and research. “AKF is pleased to continue partnering with Boehringer Ingelheim and Lilly in our efforts to help ...